Business Wire

Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Share

ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005253/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying thermally-fragile molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. (Photo: Business Wire)

“Innovation in mass spectrometry progresses rapidly. Our product introductions at this year’s ASMS benefit scientists throughout the drug development cycle,” said Jon Pratt, Senior Vice President, Waters Corporation. “For researchers, this means enhanced capability to answer fundamental scientific questions. For the analytical scientist compiling analytical data for new drug filings, it means increased certainty and confidence in knowing precisely what’s in their samples and in what quantities.”

Waters Xevo G3 QTof – A Laboratory Workhorse

The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins, peptides and other biotherapeutics.

“Biopharmaceutical development and commercialization requires a deep understanding of product variation, their degradation pathways and the processes that make them,” said Dr. Andrew Mahan, Associate Director, Mass Spectrometry Group Leader, Cell Engineering and Early Development, Janssen. “The extended mass-to-charge ratio (m/z) range of the Xevo G3 QTof is going to be ideal for the analysis of multi-specifics and for native MS analyses.”

Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts.

New Software App for Confirming Nucleic Acid Sequence of Biotherapeutics

The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.

The CONFIRM Sequence app eliminates 50% of the time it takes for post-processing data review, accelerating characterization and development of nucleic acid therapeutics.iii

The new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition, processing, and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice (GMP) labs.

Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular Characterization

The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.

The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today, giving scientists a much clearer picture of the structure of their molecules at the isotope level iv.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, Xevo, SELECT SERIES, UPLC and waters_connect are trademarks of Waters Corporation.

i Vs. the Waters Xevo G2-XS
ii For thermally-labile compounds
iii Internal estimate based on 30 minutes to review a single oligo sequence data set in CONFIRM Sequence compared to 90 minutes with ThermoFisher’s BioPharma Finder.
iv Waters SELECT SERIES MRT mass resolution >200k FWHM @ m/z 785 and independent of scan time; highest resolution achieved irrespective of scan rate

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release

SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release

The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye